285 related articles for article (PubMed ID: 22919247)
1. Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein.
La Greca G; Sofia M; Lombardo R; Latteri S; Ricotta A; Puleo S; Russello D
World J Gastroenterol; 2012 Aug; 18(31):4150-5. PubMed ID: 22919247
[TBL] [Abstract][Full Text] [Related]
2. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
Morris-Stiff G; Teli M; Jardine N; Puntis MC
Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
[TBL] [Abstract][Full Text] [Related]
3. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.
Marrelli D; Caruso S; Pedrazzani C; Neri A; Fernandes E; Marini M; Pinto E; Roviello F
Am J Surg; 2009 Sep; 198(3):333-9. PubMed ID: 19375064
[TBL] [Abstract][Full Text] [Related]
4. Serum CA19-9 measurement increases the effectiveness of staging laparoscopy in patients with suspected pancreatic malignancy.
Connor S; Bosonnet L; Alexakis N; Raraty M; Ghaneh P; Sutton R; Neoptolemos JP
Dig Surg; 2005; 22(1-2):80-5. PubMed ID: 15849467
[TBL] [Abstract][Full Text] [Related]
5. FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis.
Wannhoff A; Hov JR; Folseraas T; Rupp C; Friedrich K; Anmarkrud JA; Weiss KH; Sauer P; Schirmacher P; Boberg KM; Stremmel W; Karlsen TH; Gotthardt DN
J Hepatol; 2013 Dec; 59(6):1278-84. PubMed ID: 23958938
[TBL] [Abstract][Full Text] [Related]
6. Dynamic change of serum CA19-9 levels in benign and malignant patients with obstructive jaundice after biliary drainage and new correction formulas.
Zhao B; Cheng Q; Cao H; Zhou X; Li T; Dong L; Wang W
BMC Cancer; 2021 May; 21(1):517. PubMed ID: 33962560
[TBL] [Abstract][Full Text] [Related]
7. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
[TBL] [Abstract][Full Text] [Related]
8. Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy.
Leelawat K; Sakchinabut S; Narong S; Wannaprasert J
BMC Gastroenterol; 2009 Apr; 9():30. PubMed ID: 19405942
[TBL] [Abstract][Full Text] [Related]
9. The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma.
Singh S; Tang SJ; Sreenarasimhaiah J; Lara LF; Siddiqui A
Dig Dis Sci; 2011 Aug; 56(8):2491-6. PubMed ID: 21516323
[TBL] [Abstract][Full Text] [Related]
10. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.
Mann DV; Edwards R; Ho S; Lau WY; Glazer G
Eur J Surg Oncol; 2000 Aug; 26(5):474-9. PubMed ID: 11016469
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic utility of clinical and biochemical parameters in pancreatic head malignancy patients with normal carbohydrate antigen 19-9 levels.
Jin X; Wu Y
Afr Health Sci; 2015 Mar; 15(1):123-30. PubMed ID: 25834540
[TBL] [Abstract][Full Text] [Related]
12. CA19-9 does not predict cholangiocarcinoma in patients with primary sclerosing cholangitis undergoing liver transplantation.
Fisher A; Theise ND; Min A; Mor E; Emre S; Pearl A; Schwartz ME; Miller CM; Sheiner PA
Liver Transpl Surg; 1995 Mar; 1(2):94-8. PubMed ID: 9346547
[TBL] [Abstract][Full Text] [Related]
13. Clinical Interpretation of Elevated CA 19-9 Levels in Obstructive Jaundice Following Benign and Malignant Pancreatobiliary Disease.
Kim MS; Jeon TJ; Park JY; Choi J; Shin WC; Park SE; Seo JY; Kim YM
Korean J Gastroenterol; 2017 Aug; 70(2):96-102. PubMed ID: 28830135
[TBL] [Abstract][Full Text] [Related]
14. Can red cell distribution width help to discriminate benign from malignant biliary obstruction? A retrospective single center analysis.
Beyazit Y; Kekilli M; Ibis M; Kurt M; Sayilir A; Onal IK; Purnak T; Oztas E; Tas A; Yesil Y; Arhan M
Hepatogastroenterology; 2012; 59(117):1469-73. PubMed ID: 22683963
[TBL] [Abstract][Full Text] [Related]
15. Transpapillary biliary biopsy for malignant biliary strictures: comparison between cholangiocarcinoma and pancreatic cancer.
Chen WM; Wei KL; Chen YS; Chang PJ; Tung SY; Chang TS; Huang HC; Shen CH; Hsieh YY; Wu CS
World J Surg Oncol; 2016 May; 14():140. PubMed ID: 27142076
[TBL] [Abstract][Full Text] [Related]
16. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
17. Mucin-producing cholangiocarcinoma: clinical experience of 24 cases in 16 years.
Kuo CM; Changchien CS; Wu KL; Chuah SK; Chiu KW; Chiu YC; Chou YP; Kuo CH
Scand J Gastroenterol; 2005 Apr; 40(4):455-9. PubMed ID: 16028441
[TBL] [Abstract][Full Text] [Related]
18. [The value of CA19-9 and CEA in predicting resectability of hilar cholangiocarcinoma].
Zong D; Zeng Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Sep; 45(5):819-22. PubMed ID: 25341348
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma.
Leelawat K; Narong S; Wannaprasert J; Ratanashu-ek T
World J Gastroenterol; 2010 Oct; 16(37):4697-703. PubMed ID: 20872971
[TBL] [Abstract][Full Text] [Related]
20. Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA.
Qin XL; Wang ZR; Shi JS; Lu M; Wang L; He QR
World J Gastroenterol; 2004 Feb; 10(3):427-32. PubMed ID: 14760772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
